Clinical TrialsSearch results
Number of results: 157
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Other
- Neo-adjuvant therapy with paclitaxel followed by FEC fluoraouracil, epirubicin and cyclophosphamide) for primary breast cancer(KBC-SG0801)
- Primary breast cancer
- Kyushu Breast Cancer Study Group
- 2009-02-27
Other
- Phase II study of sequential administration of FEC (Fluorouracil / Epirubicin / Cyclophosphamide) followed by Docetaxel as adjuvant chemotherapy for node-positive breast cancer
- Breast cancer
- Kyushu Breast Cancer Study Group
- 2006-04-06
Other
- Assessment of clinical usefulness in CKD patients with atorvastatin trial (ASUCA Trial)
- Hyperlipidemia with Chronic Kidney Disease (CKD)
- Kyoto University Graduate School of Medicine
- 2009-03-17
Other
- Optimal combination of pharmacological agents for cardiovascular and renal complications of diabetes mellitus and impaired glucose tolerance
- Cardiovascular and renal complications of diabetes mellitus and impaired glucose tolerance
- Kyoto Medical Centar
- 2009-04-01
Other
- Feasibility study of Capecitabine as adjuvant chemotherapy for stage III colon cancer including RS cancer.
- stage III colon cancer including RS cancer
- KSCC
- 2008-10-22
Other
- Phase II study of combination therapy with Irinotecan and S-1 in patients with progressive colorectal cancer after FOLFOX regimen
- Unresectable advanced/recurrent colorectal cancer
- KSCC
- 2008-08-29
Other
- Safety and efficacy of Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles as First line Therapy in Advanced colorectal Cancer
- Unresectable advanced/recurrent colorectal cancer
- KSCC
- 2008-08-12
Other
- Cilostazol trial
- peripheral arterial disease
- Kokura Memorial Hospital
- 2008-06-20
Recruiting
- Therapeutic development of adrenomedullin for moderate pneumonia caused by COVID-19
- COVID-19
- Kita Toshihiro
- 2021-06-24
Recruiting
- Therapeutic development of adrenomedullin for severe pneumonia caused by COVID-19
- COVID-19
- Kita Toshihiro
- 2020-10-12